Tom Wilks

Tom Wilks is an accomplished scientist with extensive experience in assay development and epigenetics. Currently serving as the Head of Assay Development at Quotient Therapeutics, Tom leads a team focused on next-generation sequencing (NGS) assay development and automation. Previous roles include Senior Manager at Exact Sciences, where Tom oversaw a chemistry team working on the TAPS method for cancer detection, and Group Leader at the University of Birmingham, managing a 20-member research team. Tom also brings experience as a Postdoctoral Research Fellow at the University of Warwick, Midlands Regional Director at The Brilliant Club, and a PhD Researcher at the University of Warwick. An educational background includes a B.A. and M.Sci. in Natural Sciences from the University of Cambridge and a PhD in Materials Chemistry from the University of Warwick.